HEALEY ALS Platform Trial – Regimen I NUZ-001 Purpose of the study? The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. Regimen I will evaluate the safety and efficacy of a single study drug, NUZ-001, in participants with ALS. Link
HEALEY ALS Platform Trial – Regimen I NUZ-001 Read More »
Xenon X-TOLE2/X-ACT/X-TOLE4 (Active, No longer Recruiting) About the study? About Study: The Xenon studies are investigating the effect of a novel anti-seizure medication, XEN1101, on seizure frequency for patients diagnosed with Focal or Generalized Epilepsy. Patients will take either the active study drug or the placebo, and have the option to enroll in a long-term
Xenon X-TOLE2/X-ACT/X-TOLE4 Read More »
ANNOVIS Alzheimer’s Disease What is the ANNOVIS Alzheimer’s Disease Study? A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD The Goal The goal of this clinical trial is to learn if buntanetap/Posiphen works to treat early Alzheimer’s disease in adults aged 55-85. It will also learn about the safety
ANNOVIS Alzheimer’s Disease Read More »
BMS TARGET-TAU This study is being done to learn more about the safety and efficacy of an investigational medication called BMS-986446 in adults aged 50-80 years with mild cognitive impairment due to Alzheimer’s disease, or mild Alzheimer’s dementia. Inclusion Criteria: Are 50-80 years old Have a diagnosis of mild cognitive impairment due to Alzheimer’s disease,
Sanofi Freviva The purpose of this study is to determine the efficacy of frexalimab in delaying the disability progression and the safety in participants with non-relapsing secondary progressive multiple sclerosis. Inclusion Criteria: 18-60 years of age, a diagnosis of non-relapsing secondary progressive multiple sclerosis Stable immunomodulatory treatment Diagnosed within the last 10 years, without clinical
PIPELINE/CONTINEUM VISTA This is a randomized, double-blind study of PIPE-307 or placebo to see if it can help patients with relapsing-remitting multiple sclerosis. Inclusion Criteria: 18-50 years of age, a diagnosis of relapsing-remitting multiple sclerosis Stable immunomodulatory treatment Diagnosed within the last 10 years Without clinical MS relapse or treatment with corticosteroids within last 6
PIPELINE/CONTINEUM VISTA Read More »
BIOGEN CELIA In this study, researchers will learn more about a study drug called BIIB080. The study will focus on participants with mild cognitive impairment or mild dementia due to AD. The main question researchers are trying to answer is if BIIB080 can slow the worsening of AD more than placebo. It will focus on
ADCS BENFO-TEAM The purpose of this study is to learn more about the safety, effectiveness and tolerability of the study drug called Benfotiamine which may delay or slow the progression of the symptoms of early Alzheimer’s disease. Inclusion Criteria: 50 years to 89 years Mild Cognitive Impairment or Alzheimer’s Disease Availability of a designated study
Generation HD-2 This study will evaluate the safety, biomarkers, and efficacy of tominersen compared with a placebo in participants with prodromal and early manifest Huntington’s Disease. Inclusion Criteria: Visit link below for more info: Ages Eligible for Study: 25 Years to 50 Years (Adult) Sexes Eligible for Study: All Generation HD-2 Link
ADNI4 Trial The ADNI4 is multi-center, a non-randomized, natural history, non-treatment study. 1,150 participants will be enrolled across three cohorts: cognitively normal (CN), mild cognitive impairment (MCI) and dementia (DEM). Participants between the ages of 55-90 (inclusive) will be enrolled at 59 sites in the United States and Canada. Approximately, 750 participants will be newly
